Biogen Inc. vs Pfizer, Inc. — Stock Comparison

BIIB
Biogen Inc.
$191.87
▼ 1.29%
vs
PFE
Pfizer, Inc.
$26.79
▲ 2.00%
Q·Score Winner
Biogen Inc.
BIIB7.5/10vs 6.5/10

Q·Score Breakdown

7.5
Buy
Overall
6.5
Hold
7
Quality
7.4
9.7
Health
7
7.8
Growth
5.6
6.4
Valuation
6.7
6.4
Sentiment
5.2
BIIB

Clean balance sheet with low leverage (0.4× debt-to-equity).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $212.51 (+10.8%)
29 analysts
HOLD
Target $29.00 (+8.3%)
27 analysts

Fundamentals

BIIB
PFE
20.7×
Trailing P/E
19.7×
12.0×
Forward P/E
9.5×
13.8%
Profit Margin
12.4%
78.7%
Gross Margin
75.8%
7.7%
ROE
8.9%
1.9%
Revenue Growth
-1.2%
31.1%
Earnings Growth
0.16
Beta
0.39
Price / Book
$28.3B
Market Cap
$152.4B
$115 – $202
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.